Favourable interim safety data reported across three phase II clinical trials with bemcentinib in combination with KEYTRUDA® (pembrolizumab) Immune response demonstrated in AML patients treated with bemcentinib monotherapy in phase II clinical trial Two posters featuring four of BerGenBio’s six phase II clinical trials with selective AXL inhibitor bemcentinib presented at the ASCO-SITC Clinical Immuno-Oncology … Read more
Trial aims to evaluate the effectiveness of BGB324 (bemcentinib) in preventing and reversing resistance to targeted therapy Bergen, Norway, January 9, 2018 – BerGenBio ASA (OSE:BGBIO) (http://www.bergenbio.com), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the first efficacy endpoint has been met in its … Read more
Bergen, Norway, 8 January 2018 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the Company will present a corporate update during the Biotech Showcase 2018 held at the Hilton San Francisco Union Square. The presentation will include a discussion of recent progress across … Read more
Bergen, Norway, 14 December 2017 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 17 November 2017 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise options pursuant to the … Read more
Six ph II clinical trials ongoing with first-in-class highly selective AXL inhibitor BGB324. Monotherapy data at 19% RR in relapsed/refractory AML and high-risk MDS reported at ASH. 50% CBR with BGB324 in combination with erlotinib in NSCLC reported at World Lung. BGB324 in combination with docetaxel as last line therapy in NSCLC showing very promising early … Read more
35 relapsed/refractory AML and MDS patients received BGB324 as monotherapy; two CRi and five PR were observed, and seven patients stayed on treatment for more than four months. Three novel and proprietary predictive biomarker candidates were identified. Bergen, Norway, 11 Dec 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a … Read more
Bergen, Norway, 27 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, provides an update on BGBC004, an on-going, company sponsored US study evaluating BGB324 in conjunction with TARCEVA® (erlotinib) in patients with non-small cell lung cancer, in response to recent media coverage. … Read more
Bergen, Norway, 17 November 2017 – The Board of Directors in BerGenBio ASA’s (the “Company”) (OSE: BGBIO) has, to fulfil the Company’s obligations under the option agreements, resolved to increase the Company’s share capital by minimum NOK 0,10 and maximum NOK 21,500 by issuance of minimum 1 and maximum 215,000 new shares. The new shares … Read more
Bergen, Norway, 17 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the third quarter 2017. A presentation of the results by the Company’s senior management team will take place today at 9.00 am CET in Oslo – details … Read more
Bergen, Norway, 16 November 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the Company will be presenting at the Jefferies 2017 London Healthcare Conference in London, UK, on 16 November 2017. The presentation will be delivered by Richard Godfrey, CEO, and the presented … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.